Podcasts about tb hiv

The Global Fund, the world's leading financer the fight against HIV, malaria and tuberculosis has asked the Australian government to provide a $450 million commitment, as all three diseases show signs of getting worse in the Asia-Pacific region, after COVID-19. - Global Fund, pemberi sumbangan terkemuka dunia untuk memerangi HIV, malaria, dan TBC telah meminta pemerintah Australia untuk memberikan komitmen $450 juta, karena ketiga penyakit tersebut menunjukkan tanda-tanda yang semakin memburuk di kawasan Asia-Pasifik, setelah COVID-19.

The leading financer of the world's fight against HIV, Malaria and TB is asking the Australian government for a $450 million commitment, as all three diseases show signs of worsening in the region following COVID-19. The Global Fund says the diversion of resources and attention during the pandemic has threatened to undo decades of progress on other diseases across the Asia Pacific region.

The Global Fund says the diversion of resources and attention during the pandemic has threatened to undo decades of progress on other diseases across the region.

This Thursday, 24 March is World Tuberculosis Day. An estimated 9.9 million people fell ill with TB in 2020 and 1.5 million people died from the disease. TB continues to be a blight in the Indo-Pacific region, particularly in Papua New Guinea, Indonesia, Kiribati and the Republic of the Marshall Islands. Papua New Guinea bears the largest burden of disease in the Pacific, including a heavy burden of multidrug-resistant TB. In 2020 almost 30,000 cases were notified there, including 600 cases of multidrug-resistant and extensively drug-resistant TB.But TB is preventable and curable. So why is it still one of the most infectious and deadly diseases on the planet? On today's episode we are joined by three experts who are on the front line of trying to bring an end TB.Dr Mel Spigelman is the President and Chief Executive Officer of the Global Alliance for TB Drug Development – the TB Alliance – and a Member of its Board of Directors. In his time at the TB Alliance, Dr Spiegelman has been a leader in developing a regimen-based paradigm of TB drug development and leading the TB drug research field.Dr Margaret Kal is the director of the PNG National TB Program (NTP). In this role, Dr Kal is responsible for the development of all national TB guidelines, policies, research, national program reviews and all other plans and policies for TB prevention and care in PNG. Australia's Department of Foreign Affairs and Trade supports the work of the NTP.And finally, Dr Philipp du Cros is an Infectious Diseases Specialist in TB Elimination and Implementation Science at the Burnet Institute. He has extensive experience in the management of TB/HIV programs and has worked with MDR TB programs across Tajikistan, Uzbekistan, India, Myanmar, Uganda, Swaziland and Zimbabwe.The theme of World TB Day 2022 - ‘Invest to End TB. Save Lives.' We talk to all of our guests on this episode about practical ways the global community can invest to end TB and the urgent need to invest resources to ramp up the fight against TB.We hope you learn something from the conversation and join the fight to end TB @TBAlliance @CentreHealthSec

Our guests Jacob Creswell from the https://www.stoptb.org/ (STOP TB Partnership) and Brenda Mungai from the Liverpool School of Tropical Medicine, provide insight into how technology is playing a key role in TB diagnosis, and highlights from the discussion include:  The technologies currently available to help diagnose TB  The role of artificial intelligence (AI) in TB diagnosis  The involvement of communities in the development of AI and the benefits that people are seeing from these developments  Dr. Jacob Creswell is Head of Innovations & Grants at the Stop TB Partnership. He coordinates the TB REACH initiative which is focused on improving programmatic aspects of tuberculosis case detection and treatment outcomes. He serves as a global expert on different aspects of improving tuberculosis case detection including private sector engagement and active case finding. Jacob is currently working on the introduction of new diagnostic and screening tools for TB including artificial intelligence and how they can fit into more efficient and effective diagnostic algorithms. Jacob has published more than 80 scientific publication and has over 20 years of experience working at Stop TB, WHO and CDC on TB and HIV.  https://www.lstmed.ac.uk/research/centres-and-units/impala/impala-team/brenda-mungai (Dr Brenda Nyambura Mungai)  PhD candidate, Liverpool School of Tropical Medicine, Director of Tuberculosis and Lung Health  Centre for Health Solutions-Kenya  A medical doctor Bachelor's degree of Medicine and Surgery (University of Nairobi) with a postgraduate diploma in HIV management (Colleges of Medicine South Africa) and a Masters in Tropical Medicine and Infectious Diseases (Liverpool, United Kingdom). She has over fifteen years national and international professional experience in clinical care and public health approaches to management of infectious diseases especially in TB/ HIV in developing countries. Currently pursuing a PhD in Global Health at Liverpool School of Tropical Medicine focusing on operational modelling, and the role of chest X-ray and computer-aided detection software in tuberculosis screening in low -and lower-middle income countries.  

Philipp is the co-head of the Burnet Institute Tuberculosis Elimination and Implementation Science Group. He is an infectious diseases specialist with more than 15 years of extensive clinical and public health experience, and over 10 years' experience in the management of TB/HIV programs. He has worked as a TB/HIV advisor, and supported program implementation and research in a range of settings. He has worked with MDR TB programs across Tajikistan, Uzbekistan, India, Myanmar, Uganda, Swaziland and Zimbabwe. A current project is the TB Practecal Study.The TB Practecal study is a phase two, phase three study that aims to improve the treatment of multidrug resistant tuberculosis by reducing the time and using shorter treatment and less toxic regiments. Trial sites have been established working in conjunction with national health ministry's and national TB programs in Uzbekistan, Belarus and South Africa. Using new drugs, bedaquiline, delamanid, and pretomamandid the treatment for TB lasts for 6 months and does not include injections. The Practecal study also carries out public outreach programs for tuberculosis and how the public can seek effective treatment. 

Tuberkulosis masih merupakan masalah kesehatan utama di dunia. Menurut Global Report WHO, pada tahun 2012 diperkirakan 8,6 juta orang terjangkit TB dan 1,3 juta orang meninggal karena TB, termasuk 320 ribu kematian diantara orang dengan HIV positif. Hari ini di peringatan Hari Aids Sedunia, kita membahas keterkaitan antara HIV dan TB, dimana orang dengan HIV/ AIDS atau ODHA merupakan kelompok yang berisiko tinggi mengidap tuberkulosis (TB). Risiko kejadian TB akan meningkat secara signifikan dengan adanya ko-infeksi dengan HIV dan hingga kini TB adalah penyebab kematian utama pada orang dengan HIV/AIDS. Lalu bagaimana peringatan Hari Aids Sedunia ini dimanfaatkan untuk menyebarluaskan pencegahan infeksi TB pada orang dengan HIV? Dan bagaimana mengoptimalkan layanan kesehatan untuk menjangkau mereka yang beresiko tinggi TB-HIV? Akan dibahas dalam Ruang Publik KBR bersama narasumber: Yakub Gunawan - Ketua SWG (Sub Working Group) TB-HIV dan dr. Tiffany Tiara Pakasi, MA - Koordinator Subtansi Tuberkulosis, Kemenkes RI. *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

Dr. Paul Alexander joins us today to talk about Canada's crimes against humanity. Dr. Alexander worked for the government of Canada as an epidemiologist for 12 years, appointed as the Canadian in-field epidemiologist (2002-2004) as part of an international CIDA funded, Health Canada executed project on TB/HIV co-infection and MDR-TB control. Dr. Alexander is also a Covid-19 Consultant Researcher in Evidence Based Medicine. Show Resources All of my content is completely, 100%, viewer supported and funded. Thank you for your kindness to keep information like this coming.  Fear is the Virus t-shirts Donate at: www.lauralynn.tv Go Get Funding : https://bit.ly/2uZw7cD Patreon:  https://www.patreon.com/LauraLynnThompson E-Transfer to Email: lauralynnlive@gmail.com Twitter: @LauraLynnTT Facebook: Laura-Lynn Tyler Thompson Parler: @LauraLynnTT Bitchute Twitch Dlive Flote Rumble Mobcrush

In this episode, the once mild mannered Dr. Alexander exposes his true nature as a fierce lion and speaks his truth about what is happening with the global response to the wuhan flu. DO NOT MISS THIS! In today's program we continue our series on the conservation of humanity, examining the wuhan flu covid-19 scamdemic, and the tyrannical and nonsensical reaction by governments across the planet. Specifically we will be presenting a potential recovery plan, a pathway forward, to move beyond this pathetic chapter in human history. Dr. Paul E. Alexander, PhD, expertise and teaching of epidemiology (clinical epidemiology), evidence-based medicine, and research methodology (former Assistant Professor at McMaster University in evidence-based medicine); former COVID Pandemic advisor to WHO-PAHO Washington, DC (2020) and former senior advisor to COVID Pandemic policy in Health and Human Services (HHS) Washington, DC, US government; worked/appointed in 2008 at WHO as a regional specialist/epidemiologist in Europe's Regional office Denmark (nations involved in assigned WHO's project were Russia, Turkey, Ukraine, Poland), worked for the government of Canada as an epidemiologist for 12 years, appointed as the Canadian in-field epidemiologist (2002-2004) as part of an international CIDA funded, Health Canada executed project on TB/HIV co-infection and MDR-TB control (involving India, Pakistan, Nepal, Sri Lanka, Bangladesh, Bhutan, Maldives, Afghanistan); employed from 2017 to 2019 at Infectious Diseases Society of America (IDSA) Virginia USA as the evidence synthesis meta-analysis systematic review guideline development lead/trainer; education: graduate studies at University of Oxford England, University of Toronto Canada, McMaster University Canada, York University Canada; completed a short certificate program at Johns Hopkins Baltimore, USA, in bioterrorism (medical and public health aspects following the deployment of a biological weapon (weaponized pathogen such as small pox, plague, botulism, tularemia etc.) on a city such as Baltimore; also lectured and informed routinely by Dr. Donald Henderson who headed eradication of small-pox and developed expertise post the certificate program); awarded Governor General Medal of Canada for academics; doctoral studies and post doc completed under supervision of Dr. Gordon Guyatt, co-founder with Dr. Dave Sackett of the field of 'evidence-based medicine (EBM)'; currently independent academic scientist and consultant. Dr. Alexander appeared previously on the program in Episode #81, I encourage listeners to tune in to that excellent and informative episode if they have not already done so. I would like to dedicate this episode to Uncle Val Hogland, who recently passed away in Jamaica. He will be greatly missed by all his family and friends. Rest in peace Uncle Val, and God bless you. Dr. Alexander is a frequent contributor to the American Institute for Economic Research (www.aier.org) where many of his excellent detailed reports can be viewed. Some examples are as follows: https://www.aier.org/article/14-months-later-a-pathway-forward/ https://www.aier.org/article/lockdowns-are-no-substitute-for-focused-protection/ https://www.aier.org/article/the-dangers-of-masks/

In today's program we continue our series on the conservation of humanity, continuing our exploration of the wuhan flu covid-19 scamdemic. We will be dissecting the pack of lies which have been peddled globally by public health agencies, governments, mainstream media, and the mainstream medical community. Joining us today is Dr. Paul Elias Alexander. Dr. Alexander received his bachelor's degree in epidemiology from McMaster University in Hamilton, Ontario, a master's degree from Oxford University, and a PhD from McMaster University's Department of Health Research Methods, Evidence, and Impact. Dr. Paul E. Alexander, PhD, expertise and teaching of epidemiology (clinical epidemiology), evidence-based medicine, and research methodology (former Assistant Professor at McMaster University in evidence-based medicine); former COVID Pandemic advisor to WHO-PAHO Washington, DC (2020) and former senior advisor to COVID Pandemic policy in Health and Human Services (HHS) Washington, DC, US government; worked/appointed in 2008 at WHO as a regional specialist/epidemiologist in Europe's Regional office Denmark (nations involved in assigned WHO's project were Russia, Turkey, Ukraine, Poland), worked for the government of Canada as an epidemiologist for 12 years, appointed as the Canadian in-field epidemiologist (2002-2004) as part of an international CIDA funded, Health Canada executed project on TB/HIV co-infection and MDR-TB control (involving India, Pakistan, Nepal, Sri Lanka, Bangladesh, Bhutan, Maldives, Afghanistan); employed from 2017 to 2019 at Infectious Diseases Society of America (IDSA) Virginia USA as the evidence synthesis meta-analysis systematic review guideline development lead/trainer; education: graduate studies at University of Oxford England, University of Toronto Canada, McMaster University Canada, York University Canada; completed a short certificate program at Johns Hopkins Baltimore, USA, in bioterrorism (medical and public health aspects following the deployment of a biological weapon (weaponized pathogen such as small pox, plague, botulism, tularemia etc.) on a city such as Baltimore; also lectured and informed routinely by Dr. Donald Henderson who headed eradication of small-pox and developed expertise post the certificate program); awarded Governor General Medal of Canada for academics; doctoral studies and post doc completed under supervision of Dr. Gordon Guyatt, co-founder with Dr. Dave Sackett of the field of 'evidence-based medicine (EBM)'; currently independent academic scientist and consultant. Dr. Alexander is a frequent contributor to the American Institute for Economic Research (www.aier.org) where many of his excellent detailed reports can be viewed. Some examples are as follows: https://www.aier.org/article/14-months-later-a-pathway-forward/ https://www.aier.org/article/lockdowns-are-no-substitute-for-focused-protection/ https://www.aier.org/article/the-dangers-of-masks/

This episode is also available as a blog post: https://drvaishnav.com/Blog/homeopathy-no-cure-for-malria-tb-hiv/

Tuberculosis (TB) is a bacterial infectious disease that affects millions of people globally every year. Despite being one of the oldest infectious diseases in humans, control of the epidemic through treatment and vaccination has remained out of reach. In today’s episode, we learned about what makes TB so difficult to control, from immunology to stigma. First, Dr. Jun Liu, a Professor in the Department of Molecular Genetics at University of Toronto, guides us through current knowledge on TB and discusses the difficulties and advances in developing TB vaccines. Next, Dr. Amrita Daftary, a Professor in the Department of Global Health at York University, explains the process of diagnosing and treating TB, and later highlights challenges that patients with TB may face while accessing care. Finally, Dr. Sarah Fortune, the Director of TB Research Program at Harvard T. H. Chan School of Public Health, helps us understand how TB drug resistance can arise, and why TB-HIV co-infection poses such a challenge. The figure against TB continues every day, by millions of patients, healthcare providers, and researchers alike. Join us as we learn about this forgotten pandemic. Dr. Jun Liu - profile Dr. Amrita Daftary - profile Dr. Sarah Fortune - profile What is DOTS? - report Paul Farmer on Partners in Health, Harvard-Haiti, and making the lives of the poor the fight of his life TB Personal Stories Vaccine Preventable Diseases

Tuberculosis (TB) is a bacterial infectious disease that affects millions of people globally every year. Despite being one of the oldest infectious diseases in humans, control of the epidemic through treatment and vaccination has remained out of reach. In today’s episode, we learned about what makes TB so difficult to control, from immunology to stigma. First, Dr. Jun Liu, a Professor in the Department of Molecular Genetics at University of Toronto, guides us through current knowledge on TB and discusses the difficulties and advances in developing TB vaccines. Next, Dr. Amrita Daftary, a Professor in the Department of Global Health at York University, explains the process of diagnosing and treating TB, and later highlights challenges that patients with TB may face while accessing care. Finally, Dr. Sarah Fortune, the Director of TB Research Program at Harvard T. H. Chan School of Public Health, helps us understand how TB drug resistance can arise, and why TB-HIV co-infection poses such a challenge. The figure against TB continues every day, by millions of patients, healthcare providers, and researchers alike. Join us as we learn about this forgotten pandemic. Dr. Jun Liu - profile Dr. Amrita Daftary - profile Dr. Sarah Fortune - profile What is DOTS? - report Paul Farmer on Partners in Health, Harvard-Haiti, and making the lives of the poor the fight of his life TB Personal Stories Vaccine Preventable Diseases

In the first episode of the podcast, Dr. Amy Gillgrass joins us to discuss her path through academia, raising a family while pursuing research, and what it takes to start and run a laboratory. Dr. Gillgrass received her PhD at McMaster University and joined the McMaster Immunology Research Centre as an assistant professor in 2018, where she began her research program studying Immunodeficiency Virus (HIV) and Tuberculosis (TB) co-infection. Make sure to follow us on Twitter @immunoNbeyond.

In this podcast, Deepak Kaushal, PhD, talks about Mycobacterium tuberculosis and HIV coinfection, the role of CD4-positive T cells in chronic immune activation, and the macaque model his team has used to study tuberculosis infection in HIV. More at: www.consultant360.com/infectious-diseases

HSRC and partners to embark on a joint HIV and TB pilot study The Human Sciences Research Council (HSRC) and its partners will be conducting a joint TB and HIV pilot study in KwaZulu-Natal between the 26th of August and the 20th of September. The purpose of the pilot study is to determine the feasibility of conducting a larger joint Tuberculosis and Human Immunodeficiency Virus (TB/HIV) survey. The project will: • determine survey uptake of combined HIV and TB testing • assess data quality of collected interview and biomarker measures • estimate the costs of a (scaled-up) joint population-based TB/ HIV impact assessment (PHIA) survey • document operational lessons learned to inform scale up of future joint TB-HIV surveys. The survey will be taking place in 2 communities (called clusters for the purpose of the study) in Kwa-Zulu-Natal, namely Marburg and The Ridge (Umgayi). There will be 2 phases to the project: 1. Household phase, where all eligible individuals up to 500 adults (≥ 15 years as per the South African TB prevalence survey), plus their accompanying children (300 children < 15 years per cluster) will be asked to participate by answering a questionnaire. In each cluster, all households will be selected for inclusion into the pilot survey. The people who will be invited to participate will be people of all ages who have slept in that respective household for at least five nights of the previous two weeks. 2. Hub phase, where all participants who are potentially at risk of having TB will be asked to participate by having various health checks including a TB and HIV test. Where participants need to be referred to treatment and support, they will be linked to a local clinic. The survey will be anonymous, meaning that all personal identifiers will be delinked once the survey has been completed. The study aims to reach a total of 1,600 people in Kwazulu-Natal. Field workers will visit specific homes to invite members of households within the selected areas, to participate in the survey. They will also provide more information about the exact venue, date and times that the survey will be in your area. This pilot survey is very important to South Africa, as it will give an indication if HSRC and its partners can implement a larger survey in order to support efforts to find the best methods to fight TB and HIV. Community members are requested to welcome field workers, identified by their branded bibs and name tags, into their homes, and to support them in this process. For further information call: Team Leader: Ms Tsatsi Mkhombo: 081 848 9985 Project Director: Mr Shandir Ramlagan: 082 355 2379 Project PI: Dr Sizulu Moyo: smoyo@hsrc.ac.za For media enquiries or to set up interviews, please contact Adziliwi Nematandani (HRSC), 0827659191, email: anematandani@hsrc.ac.za. Join the conversation: South Africa MUST end TB and HIV #itsinourhands #endTB #endHIV # ourSouthAfrica Knowledge through research = Action

Deepak Kaushal, Ph.D. Co-infections with HIV and TB are a persistent health problem. In otherwise health people with latent TB, only 5% will go on to develop active tuberculosis. In HIV/AIDS patients, the risk of developing active TB increases ten-fold to 50%. Workers in Dr. Kaushal's lab take part in TB/HIV experiments. About a third of everyone who has HIV dies of complications from TB. Professor and Director of the Southwest National Primate Research Center, Deepak Kaushal, Ph.D. a Texas Biomed researcher, recently published a collaborative study pinpointing a possible new avenue of protection for these patients.

Join us and special guest Thokozile Phiri, powerhouse TB/HIV advocate as we discuss the importance of fully funding the Global Fund to fight AIDS, Tuberculosis, and Malaria at next month's  replenishment conference in Montreal, Canada.

This seminar will explore issues around HIV screening in TB clinics, including barriers to provider-initiated HIV testing, successful strategies to improve screening rates, and interventions for strengthening TB-HIV collaborations. The format will include an overview of the CDC's recommendations, perspectives and experiences of TB programs, and a case study. Originally recorded August 28, 2012.

This seminar will explore issues around HIV screening in TB clinics, including barriers to provider-initiated HIV testing, successful strategies to improve screening rates, and interventions for strengthening TB-HIV collaborations. The format will include an overview of the CDC's recommendations, perspectives and experiences of TB programs, and a case study. Originally recorded August 28, 2012.

This webinar explores issues around HIV screening in TB clinics, including barriers to provider-initiated HIV testing, successful strategies to improve screening rates, and interventions for strengthening TB-HIV collaborations. The format will include an overview of the CDC's recommendations, perspectives and experiences of TB programs, and a case study. Originally recorded August 28, 2012.

Tuberculosis remains a global public health threat. This session will provide public health updates from the field on some new approaches to TB diagnosis and treatment in developing countries, as well as some recent advances on such topics as child TB, community-based TB, TB-HIV, and MDR-TB.

An expert view on TB/HIV co-infection from Linda-Gail Bekker.